Century Therapeutics (IPSC) Gains from Investment Securities (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Gains from Investment Securities data on file, last reported at $5.2 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $5.2 million, up 124.35% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.2 million (changed N/A YoY), and the FY2025 annual result was $4.2 million, down 56.14% from the prior year.
• Gains from Investment Securities climbed to $5.2 million in Q1 2026 per IPSC's latest filing, from $4.2 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $5.8 million in Q4 2022 and troughed at -$84000.0 in Q4 2024.
• A 5-year average of $2.0 million and a median of $1.1 million in 2023 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities sank 107.92% in 2024, then soared 5070.77% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $5.8 million in 2022, then sank by 81.66% to $1.1 million in 2023, then sank by 107.92% to -$84000.0 in 2024, then soared by 5070.77% to $4.2 million in 2025, then rose by 25.62% to $5.2 million in 2026.
• Business Quant data shows IPSC's Gains from Investment Securities at $5.2 million in Q1 2026, $4.2 million in Q4 2025, and $1.9 million in Q3 2025.